2010 Prostate Cancer Cure?
As we enter the first weeks of 2010,
one of my favorite actors, Dennis Hopper (Easy Rider, Apocalypse Now,
Hoosiers), is losing his battle against prostate cancer while one of my
favorite Broadway composers, Andrew Lloyd Weber (Evita, Phantom of the
Opera, Jesus Christ Superstar) is winning his fight.
I've made a vow
to a few Notmilk readers. I've pledged to do my best to stay up-to-date with
leading-edge prostate cancer scientific research. These readers have become
sweet friends, while their prostate cancers represent the bitterist enemy.
My very dear friend and webmaster, Dave Rietz, died from prostate cancer
a few years ago.
I've written many columns about prostate cancer. A
key factor in the growth and proliferation of prostate cancer is a growth
hormone known as insulin-like
growth factor, or IGF-1. There are hundreds
of millions of proteins and hormones in nature, and there are 4,700
different species of mammal. The only known case of one hormone being
identical between two species is the case of human and cow. The odds of
their being one duplicate hormone between any two species is greater than
the total number of atoms in the universe, yet it happened.
contains 70 amino acids in the identical sequence in both humans and
cows. As a point of illustration, the human growth hormone and the bovine
growth hormone both contain 191 amino acids, but the sequence differs by
about 35 percent.
When humans eat milk and dairy products, they
consume that hormone identified as a key factor in prostate cancer growth.
Next month (February 15, 2010), the International Journal of Cancer will
publish a Japanese study (Kawada, et. al.) in which a substance called
Leucinostatin A inhibits prostate cancer growth by reducing IGF-I levels in
Although I will not be able to access the actual
study until the journal's publication date, what I have learned is
Researchers have conducted in vitro studies (test tube
cell cultures) and have confirmed that leucinostatins (natural antifungal
antibiotics) successfully inhibit the growth of prostate cancer cells.
The use of Leucinostatin A as a prostate cancer therapy has not yet been
approved by the Food and Drug Administration (FDA), but it is my wish that
such approval be given the fast-track FDA process.